Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Clinical Data
  • AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug
  • Clinical Data

AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug

BioSpace

New mid-stage data from Biogen's Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer's disease and raise questions that could soon be elucidated by anti-tau cand

Neuroscience

Read full story

pharminent July 15, 2026 (Last updated: July 20, 2026)

BioSpace

New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s disease and raise questions that could soon be elucidated by anti-tau cand

Neuroscience

Read full story

Post navigation

Previous: AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance
Next: Celcuity gains FDA approval for closely watched breast cancer drug

Related Stories

  • Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026
  • Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026
  • Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.